Latest News
Tempus agrees to acquire Personalis in USD1.5bn precision oncology deal
20 July 2026 - Personalis Inc (Nasdaq: PSNL), a provider of advanced genomics for precision oncology, announced on Monday that it has agreed to be acquired by technology firm Tempus AI Inc (NASDAQ: TEM) in a transaction valued at approximately USD1.5...
Acadia Pharmaceuticals announces receipt of FDA Fast Track designation for remlifanserin to treat Alzheimer's disease psychosis
20 July 2026 - Acadia Pharmaceuticals (Nasdaq: ACAD), a developer of treatments for neurological and rare diseases, revealed on Monday that it has received U.S. Food and Drug Administration Fast Track designation for remlifanserin, an investigational...
Almirall advances Ebglyss paediatric regulatory filing in Europe
20 July 2026 - Spanish pharmaceutical company Almirall S.A. (BME:ALM) said on Monday that the European Medicines Agency has accepted its submission to extend the Marketing Authorisation Application for Ebglyss (lebrikizumab) to treat children and ado...
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/JAK1 inhibitor being developed for autoimmune dise...
GSK seeks European approval for single-dose Bexsero booster in older children and adults
20 July 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Monday that the European Medicines Agency has accepted its submission to update the Bexsero label to include a single booster dose for individuals aged 10 years and o...